Tango Therapeutics (TNGX) Total Non-Current Liabilities (2020)
Tango Therapeutics (TNGX) recorded quarterly Total Non-Current Liabilities of $168.6 million in Q4 2020.
Tango Therapeutics (TNGX) Total Non-Current Liabilities (2020) Analysis & Trends
Tango Therapeutics' Total Non-Current Liabilities history runs 1 years deep, the most recent figure standing at $168.6 million for Q4 2020.
- In Q4 2020, Total Non-Current Liabilities changed N/A year-over-year to $168.6 million; the TTM figure through Dec 2020 stood at $168.6 million (changed N/A YoY), while the FY2020 annual figure was $168.6 million, changed N/A from the prior year.
- Total Non-Current Liabilities was $168.6 million for Q4 2020 at Tango Therapeutics.
- In the past five years, Total Non-Current Liabilities ranged from a high of $168.6 million in Q4 2020 to a low of $168.6 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Tango Therapeutics | 4.05 Bn | 3.67 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 168.65 Mn |